ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 574,56
-0,76%
Dow Jones
40 211,72
0,53%
DAX
18 473,12
-0,68%
Brent Oil
83,605
-0,87%
Bitcoin
62 719,74
-3,29%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Intellia Therapeutics Inc (NTLA)

  7. Intellia Therapeutics Inc (NTLA) Actualités

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NTLA
DateHeureSourceTitreSymboleSociété
17/04/202322h01GlobeNewswire Inc.Intellia Therapeutics Names Bill Chase to its Board of DirectorsNASDAQ:NTLAIntellia Therapeutics Inc
24/03/202312h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NTLAIntellia Therapeutics Inc
21/03/202313h25Dow Jones NewsIntellia Therapeutics Gets FDA RMAT Designation for NTLA-2002 in Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
21/03/202312h30GlobeNewswire Inc.Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
03/03/202323h35Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
02/03/202313h00GlobeNewswire Inc.Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)NASDAQ:NTLAIntellia Therapeutics Inc
23/02/202322h19Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:NTLAIntellia Therapeutics Inc
23/02/202322h11Edgar (US Regulatory)Annual Report (10-k)NASDAQ:NTLAIntellia Therapeutics Inc
23/02/202313h30GlobeNewswire Inc.Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
16/02/202313h30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
09/02/202317h48Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NTLAIntellia Therapeutics Inc
11/01/202313h30GlobeNewswire Inc.Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
05/01/202313h30GlobeNewswire Inc.Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key MilestonesNASDAQ:NTLAIntellia Therapeutics Inc
01/12/202211h42TipRanksHere’s Why Intellia (NASDAQ:NTLA) Stock Is Trending LowerNASDAQ:NTLAIntellia Therapeutics Inc
01/12/202203h28GlobeNewswire Inc.Intellia Therapeutics Announces Pricing of Public Offering of Common StockNASDAQ:NTLAIntellia Therapeutics Inc
30/11/202222h36GlobeNewswire Inc.Intellia Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:NTLAIntellia Therapeutics Inc
14/11/202222h35TipRanksChardan Capital Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
14/11/202215h45TipRanksIntellia Therapeutics (NTLA) Receives a Hold from BMO CapitalNASDAQ:NTLAIntellia Therapeutics Inc
12/11/202222h30GlobeNewswire Inc.Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific MeetingNASDAQ:NTLAIntellia Therapeutics Inc
10/11/202205h27TipRanksSVB Securities Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
10/11/202205h21TipRanksAnalysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), BioMarin Pharmaceutical (BMRN) and Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
07/11/202222h10TipRanksAnalysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Quest Diagnostics (DGX) and Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
07/11/202204h35TipRanksSVB Securities Keeps Their Buy Rating on Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
05/11/202221h00GlobeNewswire Inc.Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022NASDAQ:NTLAIntellia Therapeutics Inc
04/11/202215h01TipRanksAnalysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Fate Therapeutics (FATE) and Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
04/11/202213h17TipRanksJ.P. Morgan Keeps Their Buy Rating on Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
04/11/202206h05TipRanksIntellia Therapeutics (NTLA) Receives a Buy from JMP SecuritiesNASDAQ:NTLAIntellia Therapeutics Inc
03/11/202223h25TipRanksChardan Capital Remains a Buy on Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
03/11/202221h05Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NTLAIntellia Therapeutics Inc
03/11/202212h30GlobeNewswire Inc.Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA

Dernières Valeurs Consultées

LSE
JAN
Jangada Mines
LSE
QLT
Quilter
NASDAQ
ETON
Eton Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés